An observational study in Ischemic Heart Disease, sponsored by University of Aarhus. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-23.
Sponsored by University of Aarhus · Observational
The trial will include 75 patients with evident or suspected ischemic heart disease refered to Department of Nuclear Medicine \& PET Centre, Aarhus University Hospital, for perfusion imaging by 15O-H2O PET/CT scan of the heart during rest and stress. Instead of the clinical scan participants will undergo perfusion imaging by 15O-H2O PET/MR.
The clinician will receive diagnostic information based on the 15O-H2O PET scan as if the patient had not participated in the study. As such, the study has no influence on the diagnostics or treatments of the patient.
Data from the scans will be used to compare 15O-H2O PET with cardiac MR for evaluation of myocardial perfusion.
Follow up will be done for up to 10 years in regards to major cardiovascular events in order to determine the prognostic value of the scan.
3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.
This study's enrollment of 73 is below the median of 294 across 1,241 observational studies indexed under Heart Diseases.
Browse Heart Diseases studies →University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Any patient with known or suspected ischemic heart disease referred for a clinical H2O-PET at Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, not meeting any exclusion criteria will be enrolled in the study.
Exclusion Criteria:
Difference in myocardial blood flow
The difference in assessed myocardial blood flow as measured by 15O-H2O PET and MR
Time frame: 2 years
Prognostic value within 10 years
Number of participants who experience a major adverse cardiac event within 10 years of follow-up.
Time frame: 10 years
Difference in coronary flow reserve
The difference in assessed myocardial blood flow as measured by 15O-H2O PET and MR
Time frame: 2 Years
Difference in predictive value
The difference in predictive value of myocardial blood flow measurements as measured by 15O-H2O PET and MR
Time frame: 10 years
Difference in left ventricular end-systolic volume
The difference in left ventricular end-systolic volume as measured by 15O-H2O PET and MR
Time frame: 2 years
Difference in left ventricular end-diastolic volume
The difference in left ventricular end-diastolic volume as measured by 15O-H2O PET and MR
Time frame: 2 years
Difference in right ventricular end-systolic volume
The difference in right ventricular end-systolic volume as measured by 15O-H2O PET and MR
Time frame: 2 years
Difference in right ventricular end-diastolic volume
The difference in right ventricular end-diastolic volume as measured by 15O-H2O PET and MR
Time frame: 2 years
Difference in left ventricular mass
The difference in left ventricular mass as measured by 15O-H2O PET and MR
Time frame: 2 years
Amount of scar tissue
Scar tissue assessment as measured by MR
Time frame: 2 years
Pulmonary transit time
Pulmonary transit time as measured by 15O-H2O PET
Time frame: 2 years
Pulmonary perfusion
Pulmonary perfusion as measured by 15O-H2O PET
Time frame: 2 years
Prognostic value within 3,5 years
Number of participants who experience a major adverse cardiac event within 3,5 years of follow-up.
Time frame: 5 years
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Aarhus